Pharmacokinetic and Pharmacodynamics of B12019 and Neulasta® in Healthy Subjects

NCT ID: NCT02629562

Last Updated: 2017-10-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 172 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-11-30

Brief Summary

Multi-centre, double-blind, randomised, 2-way cross-over study to investigate the PK and PD of B12019 as compared to Neulasta® administered as a single subcutaneous (s.c.) dose in healthy male subjects. B12019 or Neulasta will be administered by s.c. injection.

Conditions

Clinical Pharmacology

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Arm 1

first dosing: single dose of 6mg of B12019 administered subcutaneously, second dosing: single dose of 6mg of Neulasta administered subcutaneously

Group Type: EXPERIMENTAL

B12019 and Neulasta

Intervention Type: BIOLOGICAL

GCSF, Growth Colony Stimulating Factor

Arm 2

first dosing: single dose of 6mg of Neulasta administered subcutaneously, second dosing: single dose of 6mg of B12019 administered subcutaneously

Group Type: EXPERIMENTAL

B12019 and Neulasta

Intervention Type: BIOLOGICAL

GCSF, Growth Colony Stimulating Factor

Interventions

B12019 and Neulasta

GCSF, Growth Colony Stimulating Factor

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Healthy male subjects
• Age ≥18 and ≤55 years
• BMI 22.0 - 28.0 kg/m2
• Non-smokers for at least 6 months prior to study start
• General good health, based on a comprehensive medical history and physical examination
• Adequate organ function and normal laboratory values (unless the investigator considers an abnormality to be clinically not relevant)
• Negative hepatitis B surface antigen (HBsAg), hepatitis C antibody and human immunodeficiency virus (HIV) tests at screening
• Signed informed consent

Exclusion Criteria

• Known hypersensitivity to Escherichia coli derived proteins, pegfilgrastim, filgrastim or any other component of B12019 or Neulasta®
• Previous exposure to filgrastim or pegfilgrastim
• History of drug or alcohol abuse
• Blood donations in the past 3 months prior to study start, or bone marrow or stem cell donor in the past 12 months (first dose)
• Medical history of haematological disease, including sickle cell disorders
• Recent infection (within 1 week prior to first dose)
• Relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine, inflammatory or neurological diseases, that in the opinion of the investigator may interfere with the aim of the study
• Participation in an interventional or Phase I study in the last 3 months or is current a follow-up visit schedule for any study, or has participation in more than three studies of experimental drug products in the past 12 months prior to screening
• Subjects with ANC values outside the normal laboratory range at screening
• Use of prescription or over-the-counter drugs including vitamins within 4 weeks of first dosing
• Abnormalities in ECG
• Signs of dermatitis or skin abnormalities affecting the administration area and surroundings
• History of cancer

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Cinfa Biotech

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Lissy, MD

Role: PRINCIPAL_INVESTIGATOR

Nuvisan GmbH

Locations

Nuvisan GmbH

Neu-Ulm, , Germany

Countries

Germany

Other Identifiers

B12019-101

Identifier Type: -

Identifier Source: org_study_id